Short Interest in Pharming Group (NASDAQ:PHAR) Drops By 56.9%

by · The Cerbat Gem

Pharming Group (NASDAQ:PHAR – Get Free Report) was the recipient of a large decline in short interest in March. As of March 31st, there was short interest totalling 2,500 shares, a decline of 56.9% from the March 15th total of 5,800 shares. Based on an average daily volume of 6,500 shares, the short-interest ratio is presently 0.4 days. Currently, 0.0% of the shares of the stock are sold short.

Analyst Ratings Changes

A number of analysts have recently commented on the company. Oppenheimer boosted their price objective on Pharming Group from $30.00 to $39.00 and gave the company an “outperform” rating in a research report on Friday, March 14th. HC Wainwright reissued a “buy” rating and issued a $37.00 target price on shares of Pharming Group in a research note on Thursday, March 20th.

Get Our Latest Analysis on Pharming Group

Pharming Group Trading Down 1.7 %

PHAR traded down $0.14 during trading hours on Friday, reaching $8.02. The company’s stock had a trading volume of 2,415 shares, compared to its average volume of 6,350. The stock has a market cap of $545.61 million, a PE ratio of -30.85 and a beta of -0.08. The company has a debt-to-equity ratio of 0.41, a current ratio of 3.53 and a quick ratio of 2.76. Pharming Group has a fifty-two week low of $6.65 and a fifty-two week high of $11.07. The business’s 50-day moving average is $8.53 and its 200-day moving average is $8.69.

Pharming Group (NASDAQ:PHAR – Get Free Report) last posted its quarterly earnings data on Thursday, March 13th. The company reported $0.05 earnings per share for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.02). The company had revenue of $92.70 million for the quarter, compared to analysts’ expectations of $76.67 million. Pharming Group had a negative return on equity of 7.65% and a negative net margin of 6.09%. As a group, equities research analysts predict that Pharming Group will post -0.2 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC increased its position in shares of Pharming Group (NASDAQ:PHAR – Free Report) by 16.8% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 47,997 shares of the company’s stock after buying an additional 6,887 shares during the period. Silverberg Bernstein Capital Management LLC owned about 0.07% of Pharming Group worth $483,000 at the end of the most recent reporting period. Institutional investors own 0.03% of the company’s stock.

About Pharming Group

(Get Free Report)

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.

Read More